Treatment with anticoagulants in cerebral events (TRACE)

Ralph Woessner; Markus Grauer; Oliver Bianchi; Martin Mueller; Stefan Moersdorf; Peter Berlit; Michael Goertler; Karl-Heinz Grotemeyer; Ulrich Sliwka; Martin Stoll; Johannes Treib

doi:10.1160/TH03-11-0680

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2004; 91(04): 690-693
DOI: 10.1160/TH03-11-0680

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Treatment with anticoagulants in cerebral events (TRACE)

Ralph Woessner

¹Department of Neurology, Westpfalz-Klinikum GmbH, Kaiserslautern, Germany

,

Markus Grauer

²Department of Neurology, Max-Planck Institute for Psychiatry, Munich, Germany

,

Oliver Bianchi

³Department of Neurology, SHG-Kliniken, Merzig, Germany

,

Martin Mueller

⁴Department of Neurology, University Hospital, University of the Saarland, Homburg, Germany

,

Stefan Moersdorf

⁵Department of Hemostaseology, University Hospital, University of the Saarland, Germany

,

Peter Berlit

⁶Department of Neurology, University of Essen, Germany

,

Michael Goertler

⁷Department of Neurology, University of Magdeburg, Magdeburg, Germany

,

Karl-Heinz Grotemeyer

⁸Department of Neurology, Klinikum Saarbrücken, Saarbrücken, Germany

,

Ulrich Sliwka

⁹Department of Neurology, Klinikum Remscheid, Remscheid, Germany

,

Martin Stoll

¹Department of Neurology, Westpfalz-Klinikum GmbH, Kaiserslautern, Germany

,

Johannes Treib

¹Department of Neurology, Westpfalz-Klinikum GmbH, Kaiserslautern, Germany

› Institutsangaben

Abstract

Summary

90 patients with acute stroke and a concomitant cardiac embolism source or a symptomatic high-grade stenosis of an extraor intracranial vessel received in a mulitcenter, randomized, controlled study either Enoxaparin 1 mg/kg BW s.c. b.i.d. or i.v. heparin aPTT-adjusted daily for 8 +/−2 days as secondary prophylaxis. There were no significant differences between the two groups regarding cerebral and systemic embolic events, bleeding complications, length of hospital stay, number of diagnostic and therapeutic measures and outcome after three months. This suggests that Enoxaparin, which is easier to administer and monitor, is a safe drug in patients with acute cerebral events.

Keywords

Heparin - stroke - anticoagulants

Volltext

Referenzen

References
1 Treib J, Grauer MT, Woessner R. et al. Treatment of stroke on an intensive stroke unit: a novel concept. Intensive Care Med 2000; 26: 1598-1611.
2 Estol CJ, Swanson RA. Intravenous heparin for acute stroke: What can we learn from the megatrials?. Neurology 2000; 54: 1542-6.
3 Berge E, Abdelnoor M, Nakstad PH. et al. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000; 355: 1205-10.
4 The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998; 279: 1265-72.
5 Diener HC, Ringelstein EB, von Kummer R. et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators. Stroke 2001; 32: 22-9.
6 Bath PMW, Lindenstrom E, Boysen G. et al. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet 2001; 358: 702-10.
7 Babaikain VL, Spencer M, Ackerstaff GA. et al. Basic identification criteria of Doppler microembolic signals. Stroke 1995; 26: 1123.